lung cancer
Conditions
Interventions
experimental group:amlotinib combined with carrilizumab
Sponsors
Ganyu District People's Hospital of Lianyungang City
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for advanced lung cancer, and the TNM stage is III B or IV; 2. KPS score >= 70 points; 3. The genetic test result is negative or unknown; 4. PD-L1 detection TPS >= 1% or unknown; 5. Have not used anti-angiogenesis drugs before; 6. The expected survival period is more than 3 months; 7. Disease progression after first-line chemotherapy with platinum-containing regimen (disease progression after first-line chemotherapy with EP/EC regimen, and CPT-11 intolerance or refusal of chemotherapy for second-line use).
Exclusion criteria
Exclusion criteria: 1. Central or cavitary squamous cell carcinoma, or accompanied by hemoptysis (the volume of hemoptysis> 50 ml/d); 2. Imaging shows that the tumor invades important blood vessels, or the investigator judges that the tumor is very likely to invade important blood vessels and cause fatal hemorrhage during the follow-up study; 3. Those who have experienced arterial/venous thrombotic events within 6 months, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism, central squamous cell carcinoma with cavity formation; 4. Those with serious heart, liver and kidney diseases; 5. Patients with malignant pleural effusion, pericardial effusion or superior vena cava compression syndrome; 6. Severe infection or other malignant tumors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse Event, Serious Adverse Events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall survival;Disease control rate;Objective remission rate; | — |
Countries
China
Contacts
Public ContactJi Jun'an
The Second People's Hospital of Lianyungang
Outcome results
None listed